Table 3.
Relationship between PREMIS Expectation Variables, Condom Use, and Ring Adherence by Study Visit
| PREMIS Expectation Variable | Condom Use | Adherence to Ringa | ||||
|---|---|---|---|---|---|---|
| No | Yes | Pb | No | Yes | Pb | |
| Expectation of Personal Benefit | ||||||
| 3-month visit | 0.3188 | 0.8476 | ||||
| N | 499 | 496 | 75 | 543 | ||
| Median | 70.0 | 80.0 | 74.0 | 70.0 | ||
| 25th, 75th percentile | 50.0, 100.0 | 50.0, 100.0 | 50.0, 100.0 | 50.0, 100.0 | ||
| 12-month visit | 0.3302 | 0.2049 | ||||
| N | 772 | 777 | 138 | 962 | ||
| Median | 75.0 | 80.0 | 70.0 | 75.0 | ||
| 25th, 75th percentile | 50.0, 100.0 | 50.0, 100.0 | 50.0, 95.0 | 50.0, 100.0 | ||
| Expectation of Maximum Aggregate Benefitc | ||||||
| 3-month visit | 0.2609 | 0.9062 | ||||
| N | 418 | 408 | 63 | 439 | ||
| Median | 70.0 | 70.0 | 70.0 | 70.0 | ||
| 25th, 75th percentile | 50.0, 100.0 | 50.0, 99.0 | 50.0, 95.0 | 50.0, 99.0 | ||
| 12-month visit | 0.3464 | 0.4730 | ||||
| N | 669 | 677 | 120 | 832 | ||
| Median | 75.0 | 75.0 | 60.0 | 70.0 | ||
| 25th, 75th percentile | 50.0, 99.0 | 50.0, 95.0 | 50.0, 95.0 | 50.0, 95.0 |
a
Adherence was defined as “Yes” = residual dapivirine of <23.5 mg and “No” = residual of ≥23.5;
b
P-value from Wilcoxon rank sum test;
c
The higher of the participant’s responses to items 4a and 4b.